# 

UNIFIED GLOBAL CATEGORY ORGANISATION 29 MAY 2025

### CAUTIONARY NOTE CONCERNING FORWARD – LOOKING STATEMENTS

THIS PRESENTATION AND ANY OTHER INFORMATION DISCUSSED AT THE PRESENTATION (COLLECTIVELY, THE "PRESENTATION") IS STRICTLY CONFIDENTIAL AND IS BEING PROVIDED TO YOU SOLELY FOR YOUR INFORMATION. THIS PRESENTATION MAY NOT BE PUBLISHED OR FURTHER DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, TO ANY OTHER PERSON. THE DISTRIBUTION OF THIS PRESENTATION IN CERTAIN JURISDICTIONS MAY BE RESTRICTED BY LAW AND PERSONS INTO WHOSE POSSESSION THIS PRESENTATION COMES SHOULD INFORM THEMSELVES ABOUT AND OBSERVE ANY SUCH RESTRICTIONS. IN PARTICULAR, THIS PRESENTATION IS NOT FOR PUBLICATION OR DISTRIBUTION TO US PERSONS OR INTO OR WITHIN THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR SOUTH AFRICA, OR ANY OTHER JURISDICTION WHERE, OR TO ANY OTHER PERSON TO WHOM, TO DO SO WOULD BE UNLAWFUL.

By attending the meeting where this presentation is made, or by reading the presentation slides, you agree to be bound by the following limitations:

The information in this presentation has been prepared by Reckitt Benckiser Group plc (the "Company") solely for your information. The opinions presented herein are based on general information gathered at the time of writing and are subject to change without notice. Information in this presentation sourced from third parties has been obtained from sources believed to be reliable but the Company does not guarantee its accuracy or completeness.

This presentation contains statements about future events and expectations that are forward-looking statements. These statements typically contain words such as "expects" and "anticipates" and words of similar import. Any statement in this presentation that is not a statement of historical fact is a forward-looking statement that involves known and unknown risks, uncertainties and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. None of the future projections,

expectations, estimates or prospects in this presentation should be taken as forecasts or promises nor should they be taken as implying any indication, assurance or guarantee that the assumptions on which such future projections, expectations, estimates or prospects have been prepared are correct or exhaustive or, in the case of the assumptions, fully stated in the presentation. The information and opinions contained in this presentation are provided at the date of this presentation and are subject to change without notice. There are a number of factors that could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements, including many factors outside the Company's control. Among other risks and uncertainties, the material or principal factors which could cause actual results to differ materially are: the general economic, business, political, geopolitical and social conditions in the key markets in which the Reckitt group of companies (the "Group") operates; the Group's ability to innovate and remain competitive; the Group's investment choices in its portfolio management; the ability of the Group to address existing and emerging environmental and social risks and opportunities; the ability of the Group to manage regulatory, tax and legal matters, including changes thereto; the reliability of the Group's technological infrastructure or that of third parties on which the Group relies including the risk of cyber-attack; interruptions in the Group's supply chain and disruptions to its production facilities; economic volatility including increases in tariffs and the cost of labour, raw materials and commodities; the execution of acquisitions, divestitures and business transformation projects; product safety and quality, and the reputation of the Group's global brands; and the recruitment and retention of key management. These forward-looking statements speak only as of the date of this announcement. Except as required by any applicable law or regulation, the Company expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company's expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.

### CAUTIONARY NOTE CONCERNING FORWARD – LOOKING STATEMENTS

This presentation has not been approved by any regulatory authority. This presentation does not constitute an offer to sell or issue, or any solicitation of any offer to purchase, subscribe for or otherwise acquire any securities, and nothing contained herein shall form the basis of any contract or commitment whatsoever. No reliance may be placed for any purposes whatsoever on the information contained in this presentation or on its completeness, accuracy or fairness. The contents of this presentation have not been verified by the Company. Accordingly, no representation or warranty, express or implied, is made or given by or on behalf of the Company or any of its shareholders, affiliates, directors, officers, employees, agents or advisers or any other person as to the accuracy, completeness or fairness of the information or opinions contained in this presentation. Neither the Company nor any of its shareholders, affiliates, directors, officers, employees, agents or advisers nor any other person accepts any liability (in negligence or otherwise) whatsoever for any loss howsoever arising from any use of this presentation or its contents or otherwise arising in connection therewith. In giving this presentation, neither the Company nor any of its shareholders, affiliates, directors, officers, employees, agents or advisers nor any other person undertake any obligation to provide the recipient with access to any additional information or to update this presentation or any additional information or to correct any inaccuracies in any such information which may become apparent.


This presentation is only being distributed to and is only directed at (i) persons who are outside the United Kingdom, or (ii) investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "Order"), or (iii) high net worth entities, and other persons to whom it may lawfully be communicated, falling within Article 49(2)(a) to (d) of the Order, or (iv) other persons to whom it may lawfully be communicated (all such persons (i) to (iv) being together being referred to as "relevant persons"). Any person who is not a relevant person should not act or rely on this presentation or any of its contents.

The information in this presentation is given in confidence and the recipients of this presentation should not engage in any behaviour in relation to (i) financial instruments (as defined in the Market Abuse Regulation (Regulation (EU) No 596/2014) ("MAR")) which would or might amount to market abuse for the purposes of MAR, and (ii) financial instruments (as defined in the Market Abuse Regulation (Regulation (EU) No 596/2014) as it forms part of English law by virtue of the EUWA ("UK MAR")) which would or might amount to market abuse for the purposes of UK MAR.

# CONTE KRIS LICHT CEO



### A SIMPLER, MORE EFFECTIVE CORE RECKITT









+4% TO +5% MEDIUM-TERM LFL NET REVENUE GUIDANCE FOR CORE RECKITT

### TODAY'S PRESENTERS



Chief Category Growth Officer



Pankaj Duhan
SVP Germ Protection



**Serra Bicak**SVP Self Care



SVP Household Care



# 

UNIFIED GLOBAL CATEGORY ORGANISATION 29 MAY 2025

RYAN DULLEA CHIEF CATEGORY GROWTH OFFICER



### PORTFOLIO CURATION PRINCIPLES







### RECKITT'S PORTFOLIO CONTAINS A RANGE OF WORLD-CLASS POWER-BRANDS



















SELF CARE

**GERM PROTECTION** 

HOUSEHOLD CARE

**INTIMATE WELLNESS** 

### PORTFOLIO CURATION PRINCIPLES







### WE PLAY IN STRONG CATEGORIES











### OUR CATEGORIES HAVE LONG RUNWAYS FOR GROWTH



SELF CARE

66%

people paying more attention to their health<sup>1</sup>



**GERM PROTECTION** 

**58%** 

growth in disease causing germs<sup>2</sup>









### PORTFOLIO CURATION PRINCIPLES









### RECKITT HAS SECTOR-LEADING MARGIN LEVEL (+900 BPS VS THE AVERAGE<sup>1</sup>)





### RECKITT'S GROSS MARGIN HAS REMAINED STABLE OVER THE PAST DECADE<sup>1</sup>





### WINNING PLAYBOOK









### WINNING PLAYBOOK
















RECKITT FOCUS ON



**Powerbrands** and Local Heroes





























Reflex









**TransAct** 






































### RECKITT HOLISTIC APPROACH TO BRAND BUILDING





### WINNING PLAYBOOK















### RECKITT FOCUS ON

### LEVERAGING GENERATIVE AI TO ACCESS DATA AND AMPLIFY CONSUMER UNDERSTANDING

\$\\ \frac{1}{9}\\ \frac{0}{0}\\ \text{time saving} \\ \text{on access to insights}

better quality innovation concepts



### WINNING PLAYBOOK















### WIN CONSUMER EXPERIENCE BY INVESTING IN SUPERIOR TECHNOLOGY









### WIN CONSUMER EXPERIENCE BY INVESTING IN SUPERIOR TECHNOLOGY





### HOME USE TEST TO PROVE SUPERIORITY

Winning prototype selected for market							
	RECKITT Product A	COMPETITOR PRODUCT B	PROTOTYPE 1	PROTOTYPE 2	PROTOTYPE 3	PROTOTYPE 4	PROTOTYPE 5
ATTRIBUTE A	8.58	8.43	8.65	8.61	8.68 <mark>b</mark>	8.92 ABCDeHIJ	8.81aBiJ
ATTRIBUTE B	8.16 <mark>bC</mark>	7.79	7.74	7.93	7.93	8.02	7.82
ATTRIBUTE C	8.40	8.23	8.21	8.50bcG	8.47 <b>g</b>	8.71 ABCGHIJ	8.17
ATTRIBUTE D	8.53	8.28	8.5 <mark>8</mark>	8.53 <mark>b</mark>	8.43	8.83 aBcDEGHIJ	8.53
ATTRIBUTE E	8.68	8.48	8.70	8.76 <mark>B</mark>	8.65	9.00 ABCdEGHIJ	8.67
ATTRIBUTE F	8.14	7.85	8.41 <mark>B</mark>	8.54 <mark>ABj</mark>	8.41 <mark>B</mark>	8.79 ABCdEHJ	8.60ABJ
ATTRIBUTE G	8.67	8.50	8.83 <mark>Bj</mark>	8.85 <mark>BJ</mark>	8.90 <mark>BJ</mark>	9.01ABJ	9.07 ABcdhJ
ATTRIBUTE H	8.46	8.29	8.73 <mark>aBeij</mark>	8.48	8.44	8.83 ABDEIJ	8.59j
ATTRIBUTE I	8.89	8.75	8.99 <mark>b</mark>	8.83	8.95 <mark>b</mark>	9.08Bd	9.01 <mark>B</mark>



### WINNING PLAYBOOK














CREATE AND GROW CATEGORIES THROUGH OUR WINNING PLAYBOOK



# 







Bathroom











Wipes







Sathing




Laundry

### GERM PROTECTION AT A GLANCE


£3.1bn

FY24 net revenue

31% of Core Reckitt









# 

### PANKAJ DUHAN SVP GERM PROTECTION

# HIGH GROWTH PORTFOLIO PROTECTING 25% OF GLOBAL POPULATION

#### SIGNIFICANT AND GROWING

£3.1bn

FY24 net revenue

**70/** 

FY19 - FY24 net revenue CAGR 25%

Global penetration<sup>1</sup>



#### WE ARE PIONEERS

#### SUPERIOR SCIENCE



1<sup>St</sup> used for disinfection during Spanish flu<sup>1</sup>



Dettol 1St antiseptic liquid used in hospitals for sepsis<sup>2</sup>



1St EPA approved germ kill in Air<sup>3</sup>



1St major product solution for toilet hygiene4

### WE CREATE CATEGORIES

#### **VERSATILE BRANDS**







# OUR TRUE SUPERPOWER IS "CONSUMER TRUST"

















#1 CONSIDERED
Surface care
brand<sup>5</sup>











#1 CONSIDERED
Lavatory care
brand<sup>5</sup>



#1 CONSIDERED
Lavatory care
brand<sup>5</sup>



#2 CONSIDERED
Lavatory care
brand<sup>5</sup>



# HOW TO WIN STRATEGIES



Grow penetration via iconic brands



Create categories via consumer relevance



Command premium via superior innovation



Consistently via execution excellence









#### **Driving education**

75%
Urban schools reached<sup>1</sup>

15%

Reduction in diarrhoea<sup>1</sup>

39%

Less absenteeism in school<sup>1</sup>



#### **Driving adoption**




75M+

Videos created<sup>2</sup>

**565M**+ Videos shared<sup>2</sup>


132B

Views<sup>2</sup>



# GROW PENETRATION THROUGH ICONIC BRANDS







# CREATE NEW CATEGORIES THROUGH DRIVING CONSUMER RELEVANCE





Washing with detergent alone at 30c yields little or no reduction of bacteria<sup>1</sup>

Washing Machines are a significant source of bacteria and fungi<sup>1</sup>

**Laundry Sanitizer** 

Kills 99.9%

bacteria that detergents leave behind



#### AIR

Covid can remain in air for up to 3 hours<sup>2</sup>

Air Sanitizer

1<sup>st</sup> EPA approved


germ kill in Air



# WINNING RESULTS











# CREATE NEW CATEGORIES BY DRIVING CONSUMER RELEVANCE






#### **SUPERIOR EXECUTION**








# WINNING RESULTS








NR from 2019




GM% from 2019

# PREMIUM PRICING BACKED BY SUPERIOR SOLUTIONS









# **KEY TAKEAWAYS**



Track record of business delivery



Big penetration & category creation opportunity

ス レ リ

Iconic, versatile brands to tap potential






### SELF CARE AT A GLANCE


£3.3bn

FY24 net revenue

33%

of Core Reckitt











# HOW TO WIN STRATEGY



Leverage iconic brands to close the treatment gap



Maximise winning portfolio via consumer obsession



Improve the standard of care with superior innovation



Execute with excellence across healthcare pyramid



# SERRA BICAK SVP SELF CARE

RECKITT FOCUS ON **SELF CARE** 

NUROFEN

**PAIN MANAGEMENT** 

c.£19bn

Category size<sup>1</sup>

+c.6% '20-'24 CAGR<sup>2</sup>

**GAVISCON** 

**DIGESTIVE REMEDIES** 

c.£26bn

Category size<sup>1</sup>

+c.7%

'20-'24 CAGR<sup>2</sup>

CATEGORY OF CATEGORIES

**Mucinex** 

c.£24bn

Category

size<sup>1</sup>

**Strepsils** 

+c.9%

'20-'24

CAGR<sup>2</sup>

**UPPER RESPIRATORY** 

**VMS** 

Move Free JOINT HEALTH

c.£40bn

Category size<sup>1</sup>

'20-'24 CAGR<sup>2</sup>

1. Nicholas Hall, 2024 category size 2. Nicholas Hall category CAGR



# MUCINEX - A LONG HISTORY OF SUPERIOR SOLUTIONS

# Cough & Congestion (2004)

The FIRST FDA-approved 12hr expectorant



#### Cold & Flu Day (2011)

The FIRST brand totally Max Strength



# Cold & Flu Night (2019)

The FIRST with Triprolidine (shorter sedation)



#### Cough Drops (2022)

The FIRST 4HR Cough Relief



#### Paediatric Cough (2024)

The FIRST Children's 4HR Cough Relief









### MUCINEX KICKSTART - CONSUMER NEED DRIVING CATEGORY GROWTH

#### **CONSUMER OBSESSED**

Unlocked a new morning usage occasion



#### THE INSIGHT

When sick, consumers symptoms feel their worst upon waking up



#### 7 IN 10

sufferers treat their symptoms first thing in the morning<sup>1</sup>


#### PRODUCT SUPERIORITY Mucinex Kickstart redefine how consumers start their day in the category<sup>2</sup> **59% 59%** of consumers say 44% **Mucinex Kickstart** helps them feel ready to take on the day Consumers experience fast-acting relief, by the kick of menthol All in One Competitor product








#### NUROFEN - SUPERIOR INNOVATION ALLOWING WHITE SPACE EXPANSION











#### NUROFEN - SUPERIOR INNOVATION ALLOWING WHITE SPACE EXPANSION







# **NUROFEN - WINNING IN PAIN MANAGEMENT**



# GAVISCON - BRIDGING THE TREATMENT GAP WITH SUPERIOR SCIENCE

#### **CONSUMER OBSESSED**

Suffers treat with a variety of products – from OTC Antacids to Rx PPIs



of Heartburn and Indigestion sufferers treat with OTC<sup>1</sup>



of those taking PPIs are eligible for deprescription<sup>2</sup>

#### **PRODUCT SUPERIORITY**


Superior DUAL ACTION Mode of Action



#### **SUPERIOR EXECUTION**

1) Trade up from antacids – Self-treaters education 2) Trade down from PPIs – HCPs Education

#### TRADE DOWN FROM PPIS












# GAVISCON - EDUCATION DRIVING CATEGORY GROWTH ACROSS MARKETS

#### **CONSUMER OBSESSED**

GAVISCON RELEIVES THE 7 MOST COMMON SYMPTOMS OF HEARTBURN & INDIGESTION





#### SUPERIOR HCP EXECUTION

GAVISCON – ACTIVATING 7 SYMPTOMS WITH HCPs / PHARMACIES








# GAVISCON - DELIVERING WINNING GROWTH







# Strepsils

# STREPSILS - SUPERIOR SOLUTIONS, DOING GOOD

#### **CONSUMER OBSESSED**

More occasions can be treated by medicated OTC solutions

69%

of people have experienced sore throat in the past year<sup>1</sup> 39%

of sore throat incidences are treated with medicated solutions<sup>1</sup>



#### SUPERIOR HCP EXECUTION

Drive Flurbiprofen superiority with HCPs – with BIC materials and wow demonstrations




cause of death is anti-microbial resistance<sup>2</sup>



sore throats are caused by viruses not bacteria<sup>3</sup>

# STREPSILS - WINNING IN SORE THROAT





# **KEY TAKEAWAYS**



Empowering consumers to take control of their own healthcare




Category defining iconic powerbrands well positioned for long-term growth



Bringing science to life through superior innovation



# 






# HOUSEHOLD CARE AT A GLANCE


£2.2bn

FY24 net revenue

22%

of Core Reckitt









# 

GONZALO BALCAZAR SVP HOUSEHOLD CARE



# HOW TO WIN STRATEGY



Leverage iconic brands to expand penetration



Consumer obsession focused in to solving existing pain points



Superior innovation
that enables
premiumisation,
regimen and
frequency



Execute with excellence across key touchpoints



# FINISH GROWTH MODEL: MORE HOUSEHOLDS, USING THE RIGHT PRODUCT, MORE OFTEN

#### MORE HOUSEHOLDS

**CURRENT PENETRATION COULD TRIPLE** 



Household penetration of Dishwashers. 2X more households could afford one now<sup>1</sup>



**GOLDEN RULES leveraging PARTNERS** 















#### CONSUMER OBSESSED: DEVELOPED MARKETS

#### TACKLE PROBLEMS THAT REMAIN UNSOLVED



Complain about "leftover residues" at the end of the cycle<sup>2</sup>



Complain about wet dishes at



pre-rinse dishes before loading the

#### PRODUCT SUPERIORITY: DEVELOPED MARKETS

# RIGHT PORTFOLIO WITH \$/DOSE GROWTH4





# FINISH GROWTH MODEL: MORE HOUSEHOLDS, USING THE RIGHT PRODUCT, MORE OFTEN

#### MORE HOUSEHOLDS

**CURRENT PENETRATION COULD TRIPLE** 



Household penetration of Dishwashers. 2X more households could afford one now.



**GOLDEN RULES leveraging PARTNERS** 

SIEMENS GAGGENAU DEFF (1) LG









#### **CONSUMER OBSESSED: EMERGING MARKETS**

**UNDERSTAND AND MANAGE KEY BARRIERS** 

Aware > Consider > Want

**DRIVERS** 


Saving time / convenience More effective than hand washing More hygienic

**BARRIERS** 

More expensive than hand wash Complex/ expensive installation Worse performance

#### PRODUCT SUPERIORITY: EMERGING MARKETS

BRING THE SUPERIORITY OF THE SYSTEM TO LIFE



# FINISH STRATEGY EXECUTING WITH EXCELLENCE WORKS



#### VANISH GROWTH MODEL - MORE HOUSEHOLDS, USING THE RIGHT PRODUCT, MORE OFTEN

#### PENETRATION OPPORTUNITY

BRING RELEVANCE TO THE CATEGORY



1/25 loads use Stain Remover: 1/5 Households x 1/5 loads<sup>1</sup>




In front of your eyes:

Detergent is not enough





#### VANISH STRATEGY EXECUTED WITH EXCELLENCE WORKS





#### **KEY TAKEAWAYS**



More homes PENETRATION

ス レ リ

More value per load PREMIUMISATION REGIMEN



More uses FREQUENCY



# 







#### INTIMATE WELLNESS AT A GLANCE

£1.4bn

FY24 net revenue

14% of Core Reckitt









# **ESS**

### CHARLOTTE SCHLOESING SVP INTIMATE WELLNESS

## INTIMATE WELLNESS UNLOCKS HAPPINESS







#### HOW TO WIN STRATEGY



Normalise and grow the category with iconic brands



Expand into new places and spaces via consumer obsession



Enhance experiences through superior innovations



Execute with excellence in an omnichannel world





#### NORMALISE AND GROW THE CATEGORY WITH ICONIC BRANDS

#### **CONSUMER OBSESSED**

#### LUBES ARE SEEN AS A ONE-DIMENSIONAL PROBLEM SOLVER



24% say they don't need it<sup>1</sup>
19% never considered<sup>1</sup>

More like something medical than something you'd reach for in the moment.

" I'm a bit hesitant to introduce it to our relationship.


#### **SUPERIOR SOLUTIONS & EXECUTION**

#### TURNING LUBES INTO A CATALYST FOR EXPERIENCE ENHANCEMENT





#### NORMALISE AND GROW THE CATEGORY WITH ICONIC BRANDS





#### **CONSUMER OBSESSED**

#### SEXUAL SATISFACTION IS OUR NORTH STAR



People who use Durex are

25% more satisfied

with their sex life than those who don't.(1)

People who are sexually satisfied have more sex!<sup>1</sup>

#### **SUPERIOR SOLUTIONS**

#### **BREAKTHROUGH PREMIUM INNOVATION**

Polyurethane condoms




Hyaluronic acid condoms




Benzocaine condoms











#### **CONSUMER OBSESSED**

Removing barriers to usage



#### **PRODUCT SUPERIORITY**






#### DRIVE USAGE ACROSS MORE OCCASIONS VIA CONSUMER OBSESSION

#### **CONSUMER OBSESSED**

#### High hair removal incidence



#### **SUPERIOR SOLUTIONS**

Superior solutions specifically tailored to body parts



#### WINNING RESULTS

**Body parts growth** 

#### LISX FASTERIS

than rest of range<sup>1</sup>



Contribution to 5Y growth



#### EXPERT

Veet's 1ST HAIR REMOVAL & SKINCARE KIT for full bikini area






RECKITT FOCUS ON INTIMATE WELLNESS



#### EXPERT

Veet's 1ST HAIR REMOVAL & SKINCARE KIT for full bikini area





#### ntima a



#### BUILDING FUTURE POWERBRANDS WITH OUR WINNING PLAYBOOK















#### KEY TAKEAWAYS



Highly profitable portfolio proven to deliver results



Significant runway for future growth



Leading brands shaping category and culture



RYAN DULLEA CHIEF CATEGORY GROWTH OFFICER

#### **WORLD-CLASS PORTFOLIO**



#### WINNING PLAYBOOK









#### **NEW ORGANISATION**



#### **WORLD-CLASS PORTFOLIO**



#### WINNING PLAYBOOK










#### **NEW ORGANISATION**



#### **WORLD-CLASS PORTFOLIO**



#### WINNING PLAYBOOK









#### **NEW ORGANISATION**







# 



**RECKITT FOCUS ON SERIES** 

#### RECKITT FOCUS ON: EMERGING MARKETS

#### **NITISH KAPOOR**

**President Emerging Markets** 

Date: 4 December 2025

Location: London

